{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:14:11Z","timestamp":1770833651206,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>The increasing knowledge on ulcerative colitis\u2019 pathophysiology has contributed to the expansion of the therapeutic arsenal for this condition. However, to date, 25\u201340% of patients with ulcerative colitis remain primary or secondary non\u2010responders to therapy, and up to 10% need to eventually undergo a colectomy. Janus kinase inhibitors block cytokine signalling involved in the pathogenesis of several inflammatory conditions. Tofacitinib is the first drug of this class approved for moderate\u2010to\u2010severely active ulcerative colitis in patients for whom disease worsened and those who did not improve with conventional therapy (aminosalicylates, corticosteroids and immunosuppressants) or monoclonal antibodies. We aimed to review the main aspects and concerns related to the current use of tofacitinib and to explore its future application.<\/jats:p>","DOI":"10.1177\/2050640620935732","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T08:01:11Z","timestamp":1592467271000},"page":"755-763","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Is tofacitinib a game\u2010changing drug for ulcerative colitis?"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"first","affiliation":[{"name":"Department of Biomedicine Unit of Pharmacology and Therapeutics Faculty of Medicine University of Porto Porto Portugal"},{"name":"Department of Gastroenterology S\u00e3o Jo\u00e3o Hospital Center Porto Portugal"},{"name":"MedInUP Center for Drug Discovery and Innovative Medicines Porto Portugal"},{"name":"Clinical Pharmacology Unit S\u00e3o Jo\u00e3o Hospital University Center Porto Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-0139","authenticated-orcid":false,"given":"Maria Manuela","family":"Estevinho","sequence":"additional","affiliation":[{"name":"Department of Biomedicine Unit of Pharmacology and Therapeutics Faculty of Medicine University of Porto Porto Portugal"},{"name":"Department of Gastroenterology Vila Nova de Gaia\/Espinho Hospital Center Vila Nova de Gaia Portugal"}]}],"member":"311","published-online":{"date-parts":[[2020,8]]},"reference":[{"key":"e_1_2_14_2_1","first-page":"1746","article-title":". Emerging treatments for inflammatory bowel disease","volume":"35","author":"Hazel K","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.07.003"},{"key":"e_1_2_14_4_1","article-title":"JAK\u2010STAT pathway targeting for the treatment of inflammatory bowel disease","author":"Salas A","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"e_1_2_14_5_1","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.2147\/DDDT.S182891","article-title":"Profile of tofacitinib in the treatment of ulcerative colitis: An evidence\u2010based review of recent data","volume":"13","author":"Varyani F","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_14_6_1","first-page":"2106","article-title":"Positioning tofacitinib in the treatment algorithm of moderate to severe ulcerative colitis","volume":"24","author":"Danese S","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190405141410"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1291342"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318448"},{"key":"e_1_2_14_10_1","first-page":"30414","article-title":"Small molecule oral targeted therapies in ulcerative colitis","volume":"1253","author":"Shivaji UN","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.07.009"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx133"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.10.003"},{"key":"e_1_2_14_16_1","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1093\/ecco-jcc\/jjy222.468","article-title":"P344 real\u2010world effectiveness of tofacitinib in ulcerative colitis: A multi\u2010centre study","volume":"13","author":"Ungaro R","year":"2019","journal-title":"J Crohn\u2019s Colitis"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05492-y"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15689"},{"key":"e_1_2_14_19_1","article-title":"Tofacitinib for rescue therapy in acute severe ulcerative Colitis: A real\u2010world experience.","author":"Kotwani P","journal-title":"J Crohn\u2019s Colitis"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-201710001-00640"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14422"},{"key":"e_1_2_14_22_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: Final results of a global, open\u2010label, long\u2010term extension study","volume":"21","author":"Wollenhaupt J","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.035"},{"key":"e_1_2_14_24_1","article-title":"JAK inhibitors safety in ulcerative colitis: Practical implications.","author":"Agrawal M","journal-title":"J Crohn\u2019s Colitis"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573048"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu606"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211322"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S150908"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"e_1_2_14_32_1","unstructured":"Food and Drug Administration. FDADrug Safety Communication \u2010 safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz Xeljanz XR) in rheumatoid arthritis patients https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/safety\u2010trial\u2010finds\u2010risk\u2010blood\u2010clots\u2010lungs\u2010and\u2010death\u2010higher\u2010dose\u2010tofacitinib\u2010xeljanz\u2010xeljanz\u2010xr(2019 accessed 15\u00a0May 2020)."},{"key":"e_1_2_14_33_1","unstructured":"European Medicines Agency.Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis \u2010 EMA\/180287\/2019 https:\/\/www.ema.europa.eu\/en\/documents\/press\u2010release\/increased\u2010risk\u2010blood\u2010clots\u2010lungs\u2010death\u2010higher\u2010dose\u2010xeljanz\u2010tofacitinib\u2010rheumatoid\u2010arthritis_en.pdf(2020 accessed 24\u00a0May 2020)."},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.04.059"},{"key":"e_1_2_14_35_1","first-page":"1","article-title":"Effect of tofacitinib on cardiovascular events and all\u2010cause mortality in patients with immune\u2010mediated inflammatory diseases: A systematic review and meta\u2010analysis of randomized controlled trials","volume":"11","author":"Xie W","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"e_1_2_14_36_1","first-page":"1","article-title":"Tofacitinib in the treatment of ulcerative colitis: Efficacy and safety from clinical trials to real\u2010world experience","volume":"12","author":"Amico FD","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"e_1_2_14_37_1","unstructured":"Pfizer Laboratories. Xeljanz\/Xeljanz XR (tofacitinib) \u2010 highlights of prescribing information https:\/\/www.pfizermedicalinformation.com\/en\u2010us\/xeljanz#S5.7(2019 accessed 21\u00a0May 2020)"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1592333"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0431-z"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy160"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.537"},{"key":"e_1_2_14_42_1","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1093\/ibd\/izy314","article-title":"New vaccine, new guidelines, same problem: The rates of herpes zoster infection and vaccination in IBD patients","volume":"25","author":"Greenfest A","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy150"},{"key":"e_1_2_14_44_1","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1093\/ecco-jcc\/jjz203.781","article-title":"P653 efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Updated results of the OCTAVE Open study for tofacitinib 8\u2010week induction non\u2010responders","volume":"14","author":"Rubin DT","year":"2020","journal-title":"J Crohn\u2019s Colitis"},{"key":"e_1_2_14_45_1","unstructured":"European Medicines Agency.Assessment report Xeljanz \u2010 EMA\/414633\/2018 https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/xeljanz\u2010h\u2010c\u20104214\u2010x\u20100005\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf(2018 accessed 24\u00a0May 2020)."},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15555"},{"key":"e_1_2_14_47_1","unstructured":"Food and Drug Administration. Xeljanz\/Xeljanz XR \u2010 highlights of prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf(2018 accessed 15\u00a0May 2020)."},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-019-1926-2"},{"key":"e_1_2_14_49_1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cgh.2018.11.038","article-title":"Rapid onset of tofacitinib induction therapy for the treatment of ulcerative colitis","volume":"17","author":"Griller N","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.08.017"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15005"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640620935732","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2050640620935732","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640620935732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T15:03:29Z","timestamp":1693753409000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2050640620935732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1177\/2050640620935732"],"URL":"https:\/\/doi.org\/10.1177\/2050640620935732","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}